Literature DB >> 30030936

The soluble isoform of human FcɛRI is an endogenous inhibitor of IgE-mediated mast cell responses.

S Moñino-Romero1,2, L Erkert2, K Schmidthaler1, S C Diesner1, B F Sallis2,3, L Pennington4, T Jardetzky4, H C Oettgen3,5, B Bohle6, E Fiebiger2,3, Z Szépfalusi1.   

Abstract

BACKGROUND: The soluble isoform of FcɛRI, the high-affinity IgE receptor (sFcεRI), is a protein of the IgE network with poorly defined functions.
OBJECTIVE: To define cellular sources and signals that result in the production of human sFcεRI and study its in vivo functions.
METHODS: FcεRI-transfected human cell lines (MelJuso), human monocyte-derived dendritic cells (moDCs), and murine bone marrow-derived mast cells (MC) were stimulated by FcεRI cross-linking and release of sFcεRI was analyzed (ELISA, Western Blot). Lysosomal-associated membrane protein 1 degranulation assays and human basophil activation tests (BATs) were used to study IgE-dependent activation. Recombinant sFcεRI (rsFcεRI) was used to assess its role in murine models of anaphylaxis with WT (wild-type) and IgE-/- (IgE-deficient) mice.
RESULTS: Antigen-specific cross-linking of IgE-loaded FcɛRI on MelJuso cells that express the trimeric or tetrameric receptor isoform induced the production of sFcεRI. Using MCs and moDCs, we confirmed that IgE/FcɛRI activation induces sFcɛRI release. We demonstrated that generation of sFcɛRI requires Src phosphorylation and endo/lysosomal acidification. In experimental mouse models, sFcɛRI diminishes the severity of IgE-mediated anaphylaxis. BATs confirmed that, comparable to the anti-IgE monoclonal antibody omalizumab, sFcɛRI is an inhibitor of the human innate IgE effector axis, implying that sFcɛRI and omalizumab potentially inhibit each other in vivo.
CONCLUSION: sFcɛRI is produced after antigen-specific IgE/FcɛRI-mediated activation signals and functions as an endogenous inhibitor of IgE loading to FcɛRI and IgE-mediated activation. Our results imply, therefore, that sFcɛRI contributes to a negative regulatory feedback loop that aims at preventing overshooting responses after IgE-mediated immune activation.
© 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Entities:  

Keywords:  FcεRI; IgE receptor; allergy; mast cell; omalizumab

Mesh:

Substances:

Year:  2018        PMID: 30030936     DOI: 10.1111/all.13567

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  10 in total

Review 1.  Recent developments in understanding the mechanisms of food allergy.

Authors:  Zoe C Schmiechen; Katherine A Weissler; Pamela A Frischmeyer-Guerrerio
Journal:  Curr Opin Pediatr       Date:  2019-12       Impact factor: 2.856

Review 2.  AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI).

Authors:  D Ferastraoaru; H J Bax; C Bergmann; M Capron; M Castells; D Dombrowicz; E Fiebiger; H J Gould; K Hartmann; U Jappe; G Jordakieva; D H Josephs; F Levi-Schaffer; V Mahler; A Poli; D Rosenstreich; F Roth-Walter; M Shamji; E H Steveling-Klein; M C Turner; E Untersmayr; S N Karagiannis; E Jensen-Jarolim
Journal:  Clin Transl Allergy       Date:  2020-07-17       Impact factor: 5.871

3.  CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen.

Authors:  Shiteng Duan; Cynthia J Koziol-White; William F Jester; Scott A Smith; Corwin M Nycholat; Matthew S Macauley; Reynold A Panettieri; James C Paulson
Journal:  J Clin Invest       Date:  2019-02-18       Impact factor: 14.808

Review 4.  Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management.

Authors:  Liting He; Wanyu Yi; Xin Huang; Hai Long; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2021-09-16       Impact factor: 8.667

5.  Soluble FcεRI, IgE, and tryptase as potential biomarkers of rapid desensitizations for platin IgE sensitized cancer patients.

Authors:  Sherezade Moñino-Romero; Leticia de Las Vecillas; Leila A Alenazy; Marina Labella; Zsolt Szépfalusi; Edda Fiebiger; Mariana C Castells
Journal:  J Allergy Clin Immunol Pract       Date:  2020-02-04

Review 6.  A new look at IgE beyond allergies.

Authors:  Andrea J Luker; Joseph C Lownik; Daniel H Conrad; Rebecca K Martin
Journal:  F1000Res       Date:  2019-05-24

7.  Soluble FcɛRI: A biomarker for IgE-mediated diseases.

Authors:  Sherezade Moñino-Romero; Willem S Lexmond; Josef Singer; Christina Bannert; Abena S Amoah; Maria Yazdanbakhsh; Daniel A Boakye; Erika Jensen-Jarolim; Edda Fiebiger; Zsolt Szépfalusi
Journal:  Allergy       Date:  2019-03-11       Impact factor: 13.146

8.  The relationship between released soluble FceRI-alpha and its cell surface density on human basophils.

Authors:  Donald MacGlashan
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

Review 9.  New Mechanistic Advances in FcεRI-Mast Cell-Mediated Allergic Signaling.

Authors:  Yang Li; Patrick S C Leung; M Eric Gershwin; Junmin Song
Journal:  Clin Rev Allergy Immunol       Date:  2022-10-17       Impact factor: 10.817

Review 10.  B cells and the microbiota: a missing connection in food allergy.

Authors:  Evelyn Campbell; Lauren A Hesser; Cathryn R Nagler
Journal:  Mucosal Immunol       Date:  2020-10-26       Impact factor: 8.701

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.